Will Johnson & Johnson (JNJ) Win Approval for Its Diabetes Drug?

Oh, yeah — Invokana also went head to head against Januvia in recent trials and won. That gives Johnson & Johnson an impressive track record in taking down market-leading drugs, considering that the company’s immunology drug Stelara also recently crushed Enbrel in a head-to-head study. Both drugs are great news for the company, but they represent small pieces of the entire story. And there appears to be plenty for investors to like.

The article Will Johnson & Johnson Win Approval for Its Diabetes Drug? originally appeared on Fool.com and is written by Maxx Chatsko.

Fool contributor Maxx Chatsko has no position in any stocks mentioned. The Motley Fool recommends and owns shares of Johnson & Johnson.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.